Expert Interview
A Second Opinion: Discussing Bristol Myers' COMMANDS (Reblozyl) & Geron's iMERGE (imetelstat) data from ASCO 2023 in MDS
Ticker(s): BMY, GERNInstitution: Cleveland Clinic
- Chairman, Department of Translational Hematology & Oncology Research, Professor of Medicine at Cleveland Clinic Lerner College of Medicine, and Associate Director, Lerner Research Institute
- Currently treats 50 patients with LR-MDS and 140 patients with PNH clone (47 on eculizumab)
- Has published over 150 articles as first or senior author, including papers in Nature Genetics, Blood, and Cancer Cell
Roughly how many patients with MDS do you currently manage?
Added By: chanell_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Reblozyl and Imetelstat based on the recent ASCO data?
Added By: chanell_adminDoes COMMANDS study support the broad (RS status agnostic label) in the first line for Reblozyl?
Added By: chanell_adminCould you please comment on differences in observed activity in RS negative patients between Reblozyl and KER-050 (Keros' molecule)? We are supposed to see an updated data for KER-050, Best in Class Reblozyl at EHA
Added By: chanell_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
